Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score[®] Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

· Oncotype DX[®] receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation · New guidelines reflect highest level of evidence from independent RxPONDER study, recently published in The New England Journal of MedicineMADISON, Wis., April 28, 2022 – Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has been expanded by the American Society of Clinical Oncology (ASCO) in its 2022